5 active not recruiting, 5 recruiting, 1 terminated. 6 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 2 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow 4D Molecular Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | 4D Molecular Therapeutics | 514 | 2026-09-18 | 2026-10-13 |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Recruiting | 4D Molecular Therapeutics | 480 | 2025-07-22 | 2026-10-19 |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | Active not recruiting | 4D Molecular Therapeutics | 480 | 2025-03-03 | 2026-06-01 |
| 4D-150 in Patients With Diabetic Macular Edema 4D-150 IVT, Aflibercept IVT - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Active not recruiting | 4D Molecular Therapeutics | 72 | 2023-08-09 | 2026-08-21 |
| 4D-310 in Adults With Fabry Disease and Cardiac Involvement 4D-310 - Fabry Disease | Phase 1 / Phase 2 | Recruiting | 4D Molecular Therapeutics | 18 | 2022-10-16 | 2025-02-21 |
| 4D-710 in Adult Patients With Cystic Fibrosis 4D-710 - Cystic Fibrosis Lung | Phase 2 | Recruiting | 4D Molecular Therapeutics | 30 | 2022-03-29 | 2026-07-06 |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration 4D-150 IVT, Aflibercept IVT - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | 4D Molecular Therapeutics | 215 | 2021-12-09 | 2026-08-21 |
| An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease 4D-310 - Fabry Disease | Phase 1 / Phase 2 | Active not recruiting | 4D Molecular Therapeutics | 18 | 2020-09-01 | 2024-04-08 |
| 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) 4D-125 IVT Injection, Observational - X-Linked Retinitis Pigmentosa | Phase 1 / Phase 2 | Active not recruiting | 4D Molecular Therapeutics | 21 | 2020-06-09 | 2025-03-21 |
| Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia 4D-110 - Choroideremia | Phase 1 | Active not recruiting | 4D Molecular Therapeutics | 13 | 2020-06-02 | 2025-05-22 |
| "Natural History" Study of Choroideremia Observation - Choroideremia | Terminated | 4D Molecular Therapeutics | 57 | 2016-12-01 | 2022-01-06 |
Macular Degeneration (3) · Wet Macular Degeneration (3) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Cerebral Small Vessel Diseases (2) · Cerebrovascular Disorders (2) · Choroideremia (2) · Fabry Disease (2) · Genetic Diseases, Inborn (2) · Lipid Metabolism Disorders (2) · Lipidoses (2) · Lysosomal Storage Diseases (2) · Metabolic Diseases (2) · Nervous System Diseases (2) · Sphingolipidoses (2)
aflibercept (4) · Injections (3) · Observation (1) · Watchful Waiting (1)
United States (10) · Australia (2) · Canada (2) · Japan (2) · Puerto Rico (2) · Argentina (1) · Bulgaria (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Latvia (1) · Lithuania (1)
Schonmei Lee, MD (3) · Alan H Cohen, MD (2) · Demi Dang, MD (1) · Hersh Patel (1) · Julie Clark, MD (1) · Julie Tsai, MD (1) · Sam Moskowitz MD (1)